Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib

被引：1

作者：

Fiala, Ondrej ^{[1
,5
]}

Pesek, Milos ^{[2
]}

Finek, Jindrich ^{[1
]}

Topolcan, Ondrej ^{[3
]}

Racek, Jaroslav ^{[4
]}

Svaton, Martin ^{[2
]}

Kucera, Radek ^{[3
]}

Minarik, Marek ^{[6
]}

Benesova, Lucie ^{[6
]}

Bortlicek, Zbynek ^{[7
]}

Chloupkova, Renata ^{[7
]}

Poprach, Alexandr ^{[8
,9
]}

Buchler, Tomas ^{[10
,11
,12
]}

机构：

[1] Charles Univ Prague, Dept Radiotherapy & Oncol, Prague, Czech Republic

[2] Charles Univ Prague, Dept Pneumol, Prague, Czech Republic

[3] Charles Univ Prague, Dept Nucl Med, Prague, Czech Republic

[4] Charles Univ Prague, Ist Clin Biochem & Hematol, Med Sch & Teaching Hosp Pilsen, Prague, Czech Republic

[5] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Prague, Czech Republic

[6] Genomac Res Inst, Ctr Appl Genom Solid Tumours, Prague, Czech Republic

[7] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic

[8] Masaryk Univ, Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic

[9] Masaryk Univ, Fac Med, Brno, Czech Republic

[10] Charles Univ Prague, Dept Oncol, Prague, Czech Republic

[11] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[12] Thomayer Hosp, Prague, Czech Republic

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 05期

关键词：

Lactate dehydrogenase; LDH; lung cancer; NSCLC; EGFR-TKI; erlotinib; prediction; biomarker; CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; CHEMOTHERAPY; MULTICENTER; HYPOXIA; LDH-5; EXPRESSION; MUTATIONS; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. Patients and Methods: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. Results: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). Conclusion: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.

引用

页码：2459 / 2465

页数：7

共 28 条

[1] IFCC METHODS FOR THE MEASUREMENT OF CATALYTIC CONCENTRATION OF ENZYMES .8. IFCC METHOD FOR LACTATE-DEHYDROGENASE (L-LACTATE-NAD(+) OXIDOREDUCTASE, EC-1.1.1.27) [J].